OpenLB
Open Library of Bioscience
Advanced Search
Stem cells translational medicine
Apr 15, 2024;13 (4): 317-331.

Recent Progress in Retinal Pigment Epithelium Cell-Based Therapy for Retinal Disease.

Valeriia Klymenko, Orlando G González Martínez, Marco Zarbin
Author Information
  1. Valeriia Klymenko: Institute of Ophthalmology and Visual Science, Rutgers New Jersey Medical School, Rutgers University, Newark, NJ, USA.
  2. Orlando G González Martínez: Institute of Ophthalmology and Visual Science, Rutgers New Jersey Medical School, Rutgers University, Newark, NJ, USA. ORCID
  3. Marco Zarbin: Institute of Ophthalmology and Visual Science, Rutgers New Jersey Medical School, Rutgers University, Newark, NJ, USA.
PMID: 38394392 DOI: 10.1093/stcltm/szae004

Abstract

Age-related macular degeneration and retinitis pigmentosa are degenerative retinal diseases that cause severe vision loss. Early clinical trials involving transplantation of retinal pigment epithelial cells and/or photoreceptors as a treatment for these conditions are underway. In this review, we summarize recent progress in the field of retinal pigment epithelium transplantation, including some pertinent clinical trial results as well as preclinical studies that address issues of transplant immunology, cell delivery, and cell manufacturing.

Keywords

cell transplantation embryonic stem cells geographic atrophy induced pluripotent stem cells macular degeneration retina retinal pigment epithelium retinitis pigmentosa

References

  1. Arch Ophthalmol. 2004 Apr;122(4):598-614 [PMID: 15078679]
  2. Int J Mol Sci. 2017 Mar 03;18(3): [PMID: 28273812]
  3. Clin Exp Immunol. 1988 Sep;73(3):489-94 [PMID: 3145163]
  4. J Ocul Pharmacol Ther. 2016 Jun;32(5):272-85 [PMID: 27110730]
  5. Ophthalmol Retina. 2019 Oct;3(10):850-859 [PMID: 31248784]
  6. Ophthalmology. 1983 Feb;90(2):121-5 [PMID: 6856248]
  7. J Cell Biochem. 2012 Oct;113(10):3061-8 [PMID: 22573568]
  8. Nature. 2007 Jul 19;448(7151):313-7 [PMID: 17554338]
  9. Exp Mol Med. 2019 Jan 7;51(1):1-11 [PMID: 30617277]
  10. Stem Cells. 2017 May;35(5):1176-1188 [PMID: 28220575]
  11. Cell Stem Cell. 2012 Jan 6;10(1):88-95 [PMID: 22226358]
  12. Bioact Mater. 2023 Jul 31;30:142-153 [PMID: 37575875]
  13. JAMA Ophthalmol. 2017 Mar 1;135(3):287-289 [PMID: 28196199]
  14. Med Lett Drugs Ther. 2023 Apr 3;65(1673):49-50 [PMID: 37020339]
  15. Stem Cells Transl Med. 2014 Sep;3(9):1066-78 [PMID: 25069775]
  16. Nat Biotechnol. 2024 Mar;42(3):413-423 [PMID: 37156915]
  17. Invest Ophthalmol Vis Sci. 2016 May 1;57(6):2877-87 [PMID: 27233037]
  18. Sci Transl Med. 2023 Apr 12;15(691):eadg5794 [PMID: 37043559]
  19. Cells. 2021 Oct 29;10(11): [PMID: 34831174]
  20. Cytotherapy. 2023 Jan;25(1):1-13 [PMID: 36109321]
  21. Exp Eye Res. 2005 Feb;80(2):235-48 [PMID: 15670802]
  22. Lancet. 2023 Oct 21;402(10411):1449-1458 [PMID: 37696275]
  23. Am J Ophthalmol. 2007 Apr;143(4):584-95 [PMID: 17303061]
  24. Nat Genet. 2009 Sep;41(9):968-76 [PMID: 19668214]
  25. Biomedicines. 2022 Mar 14;10(3): [PMID: 35327471]
  26. Invest Ophthalmol Vis Sci. 2016 Jul 1;57(8):3892-906 [PMID: 27472075]
  27. Nat Biotechnol. 2018 Apr;36(4):328-337 [PMID: 29553577]
  28. Sci Rep. 2015 Jul 03;5:11791 [PMID: 26138532]
  29. Nat Med. 2021 Jul;27(7):1223-1229 [PMID: 34031601]
  30. Bioengineering (Basel). 2022 Jul 04;9(7): [PMID: 35877348]
  31. Stem Cell Res. 2009 May;2(3):198-210 [PMID: 19393593]
  32. Nat Photonics. 2012 Jun 1;6(6):391-397 [PMID: 23049619]
  33. Invest Ophthalmol Vis Sci. 2013 Jul 26;54(7):5087-96 [PMID: 23833067]
  34. Stem Cell Rev Rep. 2016 Oct;12(5):553-559 [PMID: 27435468]
  35. Ophthalmology. 2018 Nov;125(11):1765-1775 [PMID: 29884405]
  36. Invest Ophthalmol Vis Sci. 2011 Jan 05;52(1):1-6 [PMID: 20688734]
  37. Genomics. 1997 Apr 15;41(2):275-8 [PMID: 9143506]
  38. Transl Vis Sci Technol. 2017 Sep 14;6(5):6 [PMID: 28920007]
  39. Eye (Lond). 1988;2 ( Pt 5):552-77 [PMID: 2476333]
  40. Stem Cell Reports. 2021 Feb 9;16(2):237-251 [PMID: 33450191]
  41. Invest Ophthalmol Vis Sci. 2004 Nov;45(11):4151-60 [PMID: 15505069]
  42. Methods Mol Biol. 2021;2239:135-151 [PMID: 33226617]
  43. Inform Med Unlocked. 2020;18: [PMID: 32864421]
  44. J Vis Exp. 2017 Oct 30;(128): [PMID: 29155780]
  45. STAR Protoc. 2022 Jul 20;3(3):101582 [PMID: 35880133]
  46. Transl Vis Sci Technol. 2017 Jun 20;6(3):22 [PMID: 28660097]
  47. Ophthalmology. 2012 Dec;119(12):2537-48 [PMID: 23084240]
  48. Ophthalmic Res. 2012;48(4):186-91 [PMID: 22868580]
  49. Stem Cell Res Ther. 2022 Sep 5;13(1):454 [PMID: 36064625]
  50. Ophthalmic Surg Lasers Imaging Retina. 2016 Apr 1;47(4):342-51 [PMID: 27065374]
  51. Transl Vis Sci Technol. 2021 Aug 12;10(10):13 [PMID: 34613357]
  52. Biomaterials. 2014 Dec;35(37):9777-9788 [PMID: 25220295]
  53. Int J Mol Sci. 2016 Feb 06;17(2):226 [PMID: 26861316]
  54. N Engl J Med. 2017 Mar 16;376(11):1038-1046 [PMID: 28296613]
  55. Am J Ophthalmol. 2015 Jul;160(1):85-93.e3 [PMID: 25857680]
  56. Stem Cell Reports. 2020 Apr 14;14(4):648-662 [PMID: 32197113]
  57. Ophthalmology. 2020 Feb;127(2):186-195 [PMID: 31474439]
  58. Ophthalmology. 2003 Jun;110(6):1151-8 [PMID: 12799240]
  59. Sci Transl Med. 2018 Apr 4;10(435): [PMID: 29618560]
  60. Cells. 2023 May 27;12(11): [PMID: 37296606]
  61. Retina. 2023 Feb 1;43(2):263-274 [PMID: 36223778]
  62. Prog Retin Eye Res. 2015 Sep;48:1-39 [PMID: 26113213]
  63. Ophthalmology. 2012 Jun;119(6):1199-210 [PMID: 22449572]
  64. Lancet Glob Health. 2014 Feb;2(2):e106-16 [PMID: 25104651]
  65. Nature. 2022 May;605(7909):325-331 [PMID: 35418683]
  66. Br J Ophthalmol. 2017 Jan;101(1):25-30 [PMID: 27491360]
  67. Dev Ophthalmol. 2014;53:155-66 [PMID: 24732769]
  68. Cells. 2022 Feb 24;11(5): [PMID: 35269421]
  69. Expert Opin Biol Ther. 2018 Oct;18(10):1049-1059 [PMID: 30129371]
  70. Stem Cells Transl Med. 2015 Jan;4(1):10-20 [PMID: 25411476]
  71. Science. 2008 Nov 7;322(5903):949-53 [PMID: 18845712]
  72. Am J Hum Genet. 1999 Feb;64(2):422-34 [PMID: 9973280]
  73. Invest Ophthalmol Vis Sci. 2018 Mar 1;59(3):1374-1383 [PMID: 29625461]
  74. Mol Ther. 2019 Apr 10;27(4):729-734 [PMID: 30598301]
  75. Transl Vis Sci Technol. 2016 Nov 22;5(6):7 [PMID: 27917311]
  76. Invest Ophthalmol Vis Sci. 1998 Sep;39(10):1823-34 [PMID: 9727405]
  77. Ophthalmology. 1993 Oct;100(10):1519-35 [PMID: 7692366]
  78. Stem Cell Reports. 2022 Mar 8;17(3):448-458 [PMID: 35120620]
  79. Cell Prolif. 2021 Sep;54(9):e13100 [PMID: 34347352]
  80. Int J Mol Sci. 2021 Mar 22;22(6): [PMID: 33810153]
  81. Sci Rep. 2021 Jan 12;11(1):692 [PMID: 33436892]
  82. Stem Cell Reports. 2015 May 12;4(5):860-72 [PMID: 25937371]
  83. Nat Methods. 2010 Mar;7(3):197-9 [PMID: 20139967]
  84. Transl Vis Sci Technol. 2021 Aug 12;10(10):15 [PMID: 34724034]
  85. Nat Rev Drug Discov. 2016 Jun;15(6):385-403 [PMID: 26775688]
  86. Cells. 2023 Jun 22;12(13): [PMID: 37443724]
  87. Nat Genet. 1997 Mar;15(3):236-46 [PMID: 9054934]
  88. Lancet. 2015 Feb 7;385(9967):509-16 [PMID: 25458728]
  89. J Clin Invest. 2020 Feb 3;130(2):1010-1023 [PMID: 31714897]
  90. Invest Ophthalmol Vis Sci. 1999 Mar;40(3):775-9 [PMID: 10067983]
  91. Proc Jpn Acad Ser B Phys Biol Sci. 2009;85(8):348-62 [PMID: 19838014]
  92. Ophthalmology. 2011 Nov;118(11):2227-37 [PMID: 22047893]
  93. J Neural Eng. 2021 Mar 16;18(3): [PMID: 33592588]
  94. J Clin Med. 2020 Jul 13;9(7): [PMID: 32668747]
  95. Mol Vis. 2001 Feb 07;7:14-9 [PMID: 11182021]
  96. Stem Cell Reports. 2017 Jul 11;9(1):42-49 [PMID: 28625537]
  97. Br J Ophthalmol. 2021 Jun;105(6):829-837 [PMID: 32727729]
  98. Stem Cells Transl Med. 2021 Feb;10(2):198-208 [PMID: 32946199]
  99. Am J Ophthalmol. 1982 Jul;94(1):91-6 [PMID: 7091289]
  100. Curr Stem Cell Rep. 2015 Jun;1(2):79-91 [PMID: 26146605]
  101. Invest Ophthalmol Vis Sci. 2016 Apr 1;57(5):ORSFc1-9 [PMID: 27116660]
  102. In Vitro Cell Dev Biol Anim. 2020 Jan;56(1):85-95 [PMID: 31768763]

MeSH Term

Humans
Retinal Pigment Epithelium
Stem Cell Transplantation
Retinal Diseases
Retina
Macular Degeneration
Review Journal Article

Word Cloud

Created with Highcharts 10.0.0retinaltransplantationpigmentcellscellmaculardegenerationretinitispigmentosaclinicalepitheliumRetinalstemAge-relateddegenerativediseasescauseseverevisionlossEarlytrialsinvolvingepithelialand/orphotoreceptorstreatmentconditionsunderwayreviewsummarizerecentprogressfieldincludingpertinenttrialresultswellpreclinicalstudiesaddressissuestransplantimmunologydeliverymanufacturingRecentProgressPigmentEpitheliumCell-BasedTherapyDiseaseembryonicgeographicatrophyinducedpluripotentretina

Similar Articles

Cited By